A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Recruiting now

Conditions studied: EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases

In brief

This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

Key facts

Study ID

NCT07143045

Run by

Alpha Biopharma (Jiangsu) Co., Ltd.

People needed

800

Starts

2025-12-29

Expected to finish

2031-11-01

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged ≥18 years.
• Histologically or cytologically confirmed NSCLC with EGFR sensitizing mutations (including L858R or Exon 19Del), ineligible for curative surgery or radiotherapy.
• CNS metastases diagnosed as brain metastases (BM) and/or leptomeningeal metastases (LM) by imaging and/or cerebrospinal fluid pathological examination.
• Planning to receive zorifertinib (zorifertinib group) or other anti-tumor treatments (other treatment group) as first-line treatment.
• Voluntarily agreeing to participate in this study and signing the informed consent form.

You may not qualify if…

• Currently participating or planning to participate in any interventional clinical study for first-line treatment (patients who have participated in non-interventional, real-world studies may still be included).
• Other reasons that, in the Investigator's opinion, make the patient unsuitable for this study.
• For patients in Cohort A of the zorifertinib group, the following inclusion/exclusion criteria of the EVEREST study must also be met:
• Inclusion Criteria A:
• . No prior treatment with chemotherapy, EGFR-TKIs, biological therapy, immunotherapy, or any investigational drug that is considered first line treatment for advanced NSCLC.
• . Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician.
• . All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.
• . Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir.
• . ECOG performance status 0 or 1, with no deterioration over the past 2 weeks, and expected survival time ≥ 3 months.
• . Women of child-bearing potential (WOCBP) and male patients should agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All WOCBP must have a negative pregnancy test at screening.
• . Patients with measurable CNS lesions must have at least one site of CNS lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI, and is suitable for accurate repeated measurements. Measurable extracranial lesions are not required. Patients with non-measurable CNS lesions must have at least one extracranial lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except for lymph nodes which must have a short diameter ≥ 15 mm) by CT/MRI, and is suitable for accurate repeated measurements.
• Exclusion Criteria A:
• . Prior treatment with EGFR-TKIs (if EGFR-TKIs were used as adjuvant therapy, patients may be enrolled if the time from discontinuation to relapse meets the following requirements: >6 months for Cohort A, and >3 months for Cohorts B and C).
• . Positive for T790M mutation documented by central or local laboratory using an approved or validated test method, or documented positive KRAS or cMET.
• . Patients who have received any investigational drug, biological therapy, or immunotherapy for their malignant tumors within the past 21 days.
• . Patients who have had a major surgical procedure (excluding the need for placement of vascular access or a CNS shunt), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study.
• . Presence of only leptomeningeal metastases (LM) disease confirmed by MRI and/or positive cerebrospinal fluid (CSF) pathology, with no brain metastases (BM).
• . Prior radiation therapy for CNS metastases that involves measurable or non-measurable sites of disease to assess efficacy.
• . Patients who have received radiation to more than 30% of the bone marrow within 2 weeks before the first dose of study treatment.
• . Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study treatment) certain medications or herbal supplements that are known to be potent inhibitors or inducers of CYP3A4/5 (see Appendix A).
• . Unmanageable nausea and vomiting, chronic gastrointestinal diseases, or prior gastric resection or surgical procedure that may interfere with adequate absorption of study drug.
• . History of concurrent and/or other active malignant tumors requiring treatment within 5 years of study treatment, excluding prior treated squamous cell carcinoma or basal cell carcinoma or carcinoma in situ.
• . History of any type of documented interstitial lung disease or radiation pneumonitis.
• . Presence of any severe or uncontrolled systemic disease or condition, including: (i) uncontrolled hypertension or diabetes; (ii) serious cardiac, pulmonary or renal disorders; (iii) active bleeding diatheses; (iv) any active type of bacterial, viral, fungal or other infection that would pose a significant risk to the patient in the opinion of the Investigator; or (v) active hepatitis B virus positive (defined as hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and hepatitis B DNA positive (or detectable) or above the cut-off value) or positive HCV antibodies or positive HIV test result.
• . Women who are pregnant or lactating. WOCBP and fertile men with a WOCBP-partner not using adequate contraception measures.

Where it is running

• Meizhou People's Hospital — Meizhou, Guangdong, China (enrolling)
• Foshan First People's Hospital — Foshan, Guangdong, China (enrolling)
• Capital Medical University Affiliated Beijing Chest Hospital — Beijing, Beijing Municipality, China (enrolling)
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
• Fujian Cancer Hospital — Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China
• Heyou Hospital, Shunde District, Foshan City — Foshan, Guangdong, China
• Affiliated Cancer Hospital of Guangxi Medical University — Nanning, Guangxi, China
• The First Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi, China
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
• Henan Cancer Hospital — Zhenzhou, Henan, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China
• Hunan Cancer Hospital — Changsha, Hunan, China
• Xiangya Hospital, Central South University — Changsha, Hunan, China
• Jiangsu Provincial People's Hospital — Nanjing, Jiangsu, China
• Nanjing Chest Hospital — Nanjing, Jiangsu, China
• Northern Jiangsu People's Hospital — Yangzhou, Jiangsu, China
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China
• First Hospital of Jilin University — Changchun, Jilin, China
• The First Hospital of China Medical University — Shenyang, Liaoning, China
• Dalian University of Technology Affiliated Central Hospital (Dalian Central Hospital) — Dalian, Shandong, China
• Qingdao University Affiliated Hospital — Qingdao, Shandong, China
• Shanxi Bethune Hospital — Taiyuan, Shanxi, China
• Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences — Shenzhen, Shenzhen, China
• Shenzhen Third People's Hospital — Shenzhen, Shenzhen, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.